Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Delayed Data from NSDQ)

$143.71 USD

143.71
489,265

-0.09 (-0.06%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $143.66 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3

by Zacks Equity Research

Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.

Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of -78.49% and 7.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD & More

by Zacks Equity Research

Let's analyze how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Oct 27.

Analysts Estimate Harmony Biosciences Holdings, Inc. (HRMY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q3 Earnings Expected to Decline

by Zacks Equity Research

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alnylam (ALNY) Soars 3.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion

by Zacks Equity Research

The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

by Zacks Equity Research

The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study

by Zacks Equity Research

Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.

Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why

by Zacks Equity Research

Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q2

by Zacks Equity Research

Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.

Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of -41.36% and 13.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE & More

by Zacks Equity Research

Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.

Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis (IONS) Partner to Begin Phase III Study on Kidney Drug

by Zacks Equity Research

Ionis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the treatment of IgAN after announcing positive data from a phase II study.

The Zacks Analyst Blog Highlights ConocoPhillips SAP, CSX, Alnylam Pharmaceuticals and NVR

by Zacks Equity Research

ConocoPhillips, SAP, CSX, Alnylam Pharmaceuticals and NVR are part of Zacks top Analyst Blog.

Mark Vickery headshot

Top Research Reports for ConocoPhillips, SAP & CSX

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including ConocoPhillips (COP), SAP SE (SAP), and CSX Corporation (CSX).

Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod

by Zacks Equity Research

The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study

by Zacks Equity Research

Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.

Amgen (AMGN) Olpasiran Lowers Lipoprotein Levels in Phase II

by Zacks Equity Research

Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of cardiovascular events.

Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition

by Zacks Equity Research

Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.